Investable MedTech segments for 2026

MedTech capital allocation is at a turning point. While early-stage funding remains constrained, scalable platforms with validated, differentiated technology are commanding record valuations. For investors and R&D leaders, recognizing where capital is flowing – and why – will help shape strategic priorities for 2026.

The past 12 months saw fewer but larger deals, with average deal sizes increasing despite total M&A spend remaining below historical norms. MedTech VC funding followed a similar trend. While $12 billion was raised across 647 deals in the first nine months of 2025, deal counts fell as capital concentrated in later-stage platforms. This pattern is also evident in PE, with $7.4 billion invested across 75 deals in the first nine months of 2025.

Understanding which parts of the MedTech landscape align with these funding dynamics is key to predicting where investments will be made in transformative R&D programs. For this article we have chosen three segments that stand out for their growth and innovation potential: surgical systems, diagnostic platforms, and neurotechnology. Technological maturity, clear clinical demand, and scalable business models put them all in a strong position. Sagentia Medical explores what lies ahead for these segments.

Surgical systems enter a new competitive phase

With strong growth predicted, new challenger systems emerging, and acquisitions reshaping the landscape, surgical robotics is poised for more intense competition and technological evolution in 2026.

Intuitive remains formidable. The company installed 427 new da Vinci systems in Q3 2025, bringing the global installed base to more than 10,500 with 20% growth in procedures year-on-year. What’s more, a growing instruments business provides recurring revenue to strengthen its commercial position.

But competition for Intuitive’s soft tissue robotics market dominance is heating up. FDA clearance of Medtronic’s Hugo surgical robot sets it up for US market entry following successful international deployments across 25 countries. Hugo’s modular architecture is a counterstrategy to da Vinci’s integrated tower systems. Each robotic arm is mounted on a mobile cart, enabling flexible Operating Room (OR) configurations and incremental capital deployment. The latter is especially beneficial for mid-tier hospitals which face tighter financial constraints. Further competition in the US market should be expected from CMR Surgical, whose Versius Plus robotic surgical system has received FDA clearance for cholecystectomy procedures. The systems have already been used to complete over 40,000 surgical procedures globally and US commercialization will begin in earnest in 2026. These platforms join others already competing with da Vinci in the US, notably Moon Surgical’s Maestro system and Distalmotion’s DEXTER. Both Maestro and Dexter have been positioned for use in lower acuity procedures and simplified workflows, offering advantages in outpatient settings.

Surgical robotics competition increasingly centers on OR integration. Capabilities around tower integration, advanced vision systems, energy instruments, endocutters, data analytics and real-time data fusion are commanding attention with their ability to reduce surgeons’ cognitive load and standardize OR equipment.

On the orthopedic front, the migration of large joint procedures to Ambulatory Surgery Centers (ASCs) continues. Stryker’s Mako platform currently dominates the high-volume segments of knee and hip arthroplasty, but it is not unchallenged. Zimmer Biomet’s acquisition of AI-driven orthopedic robotics company Monogram provides a route to more autonomous robotics and builds on its distribution agreement for TMINI, the ASC-optimized handheld robot for total knee arthroplasty.

The Society of Robotic Surgery (SRS) conference always provides a showcase for emerging trends in the industry. The Shark Tank event at its annual meeting in 2025 shone a light on emerging segments and likely targets of future deals. The applications of surgical robotics have been diversifying, and it was notable that the winner of SRS’s Shark Tank was Vitestro, presenting its system for the automation of blood draw. The applications of the systems presented by other participating companies included ophthalmic surgery, dental aesthetics and ultrasound-guided needle procedures, a truly diverse implementation of ‘medical robotics’.

Developments like these are indicative of the opportunities and risks at play in this segment. Companies with validated robotic platforms at commercial scale could become acquisition targets, but incremental robotics innovation without clear strategic differentiation faces an uphill battle.

What to watch in 2026: Bundled instrument deals and outpatient optimized systems are likely to emerge as challengers look to break Intuitive’s installed base advantage. As robotic assistance expands into more procedures in soft tissue surgery, instrument companies without robotic capabilities risk losing market share. This dynamic could fuel further acquisitions of platforms with regulatory clearance and commercial traction. New segments will also see investments activity; in particular, the endoluminal, microsurgery and neurovascular segments appear well positioned for robotic deals.

Diagnostics moves towards scalable liquid biopsy adoption

As liquid biopsy technologies mature there is, at last, increased potential for large scale adoption.

From a technical perspective, the convergence of next-generation sequencing capabilities and AI-driven pattern recognition enables sensitivity levels previously unattainable. Early-stage mutations present in blood at very low concentrations can now be detected, bringing the new challenge of interpreting results to deliver clinically actionable insights. AI is increasingly embedded not just in signal detection but in clinical decision support and workflow automation, helping clinicians triage multi-cancer signals and reduce false positives.

This momentum is reflected in both strategic capital allocation and VC funding over the past 12 months. In January 2025, Oxford Cancer Analytics raised $11 million to commercialize minimally invasive liquid biopsy tests for early lung cancer detection. In November, Roche Diagnostics secured access to Freenome’s blood-based cancer screening assays outside the US, in exchange for a potential $200 million investment. The partnership will explore Roche’s SBX technology as a future environment for Freenome’s tests. Soon after, Abbott announced its proposed $21 billion acquisition of Exact Sciences, which would become the largest MedTech acquisition to date. Together, these moves reinforce the view that early cancer screening will be a foundational component of future healthcare systems.

Steps are also being taken towards hypothesis-free testing. GRAIL’s Galleri test exemplifies progress that has been made here. The assay, which screens for more than 50 cancer types with a single blood draw, has moved from pilots into national early detection strategies across the US. This represents a fundamental rethink of cancer screening, leveraging cell-free DNA (cfDNA) methylation patterns to detect cancers before symptoms emerge. Significant challenges remain, however. Critics point to unresolved issues around false positives, cost-effectiveness, and integration into clinical workflows. Until longitudinal outcome data and reimbursement clarity emerge, adoption may be slower than headlines suggest.

Liquid biopsy developments are also changing cancer diagnosis pathways and the monitoring of Minimal Residual Disease (MRD). NHS England’s new ‘blood test first’ policy for patients with suspected lung cancer and advanced breast cancer sees circulating tumor DNA (ctDNA) testing performed before tissue biopsy. This allows patients to receive targeted therapy up to 16 days faster, with pilot data indicating potential NHS cost savings of $14.8 million annually. In terms of MRD monitoring, Natera’s Signatera Genome-MRD test, launched in April 2025, enables longitudinal tracking, impossible to achieve with tissue biopsy.

Investment is following clinical validation. Natera has strengthened its portfolio of MRD offerings through the $450m acquisition of Foresight Diagnostics. Earlier this year Foresight’s clinical data led to its ctDNA-based MRD tests being included in the National Comprehensive Cancer Network Clinical Practice Guidelines for diffuse large B-cell lymphoma.

Beyond cfDNA, multi-omic approaches combining DNA methylation, protein biomarkers, and fragmentomics are gaining traction, as seen in Freenome’s platform. Exosome-based diagnostics are emerging as a complementary modality, offering insights into tumor biology and even neurodegenerative disease pathways. These technologies, coupled with AI-driven interpretation, will be critical for scaling hypothesis-free screening without overwhelming clinical workflows.

Global momentum is building with Japan and Germany piloting cfDNA-based screening programs. Regulatory frameworks are evolving too: the FDA is signaling openness to real-world evidence for Multi-Cancer Early Detection (MCED) tests and CMS is exploring reimbursement pilots.

What to watch in 2026: We expect consolidation among smaller liquid biopsy players that lack the capital to execute large-scale clinical validation studies and navigate reimbursement complexity. Meanwhile, platform leaders with diversified panels and FDA breakthrough designations are likely to attract late-stage growth capital or strategic acquisition interest. Yet it’s important to note that reimbursement remains inconsistent and complex, creating a major barrier to broader adoption. One study of private payer and Medicare policies found that among 40 policies addressing cancer progression, coverage was provided in only 28% of cases. The winners will be those who can navigate a path to reimbursement.

Neurotech makes progress towards early commercial deployment

Neurotech investment surged in 2025, with capital flowing into Brain Computer Interface (BCI) platforms that integrate miniaturized hardware and adaptive software.

Three distinct neurotech approaches are attracting investors: invasive implants, minimally invasive endovascular systems, and non-invasive wearables. During 2026, commercial pilots in specific indications are likely, supported by rich real‑world datasets and reimbursement dialogues.

The flag bearer in this segment is Neuralink. Its $650 million Series E funding and $9 billion valuation in June 2025 dominated headlines, but the more important story centers on advancements made in human trials. From an engineering perspective, the challenges Neuralink has solved extend well beyond its core technology. The company also developed a surgical robot capable of automatically inserting thread-like electrodes into cortical tissue while avoiding vasculature – a feat requiring sub-millimeter precision.

Meanwhile, Synchron raised $200 million in Series D funding in November 2025, bringing total funding to $345 million. Its minimally invasive Stentrode system involves the insertion of an endovascular BCI, avoiding the need for open brain surgery. The BCI is delivered via catheter through the jugular vein into brain vasculature, where it records neural activity from within blood vessels adjacent to the motor cortex.

This approach significantly reduces surgical risk, anesthesia time, and recovery period. For patients with paralysis caused by Amyotrophic Lateral Sclerosis (ALS), stroke, or spinal cord injury, the ability to enable digital communication without craniotomy is transformative. Synchron is also developing next-generation interfaces designed to record neural activity data from across the brain, increasing the number of channels from tens to hundreds or even thousands, all via endovascular access.

Synchron’s Stentrode has FDA Breakthrough Device Designation and Neuralink gained an Investigational Device Exemption (IDE) to begin human trials. Yet neurotech still faces a high level of regulatory uncertainty. Achieving FDA approval demands robust evidence of safety and effectiveness, which poses particular challenges for BCIs given their limited pre-market data and novel engineering approaches.

2025 saw FDA approval of Medtronic’s Percept adaptive deep brain stimulation system for Parkinson’s. This monitors neural activity in real time and automatically adjusts therapy to provide better control of symptoms and extend battery life. As we move through 2026, a new generation of companies is extending this principle with more sophisticated control algorithms and higher fidelity sensing for adaptive neuromodulation. Many will be looking to optimise existing therapies and reduce the delays associated with physicians-in-the-loop. Others are looking at novel applications such as Coherence which has raised US $10 million seed funding to develop a bi-directional closed-loop platform (SOMA-1), aimed at reading and modulating disease-related neural signals, focusing initially on glioblastoma.

What to watch in 2026: Regulatory progress will shape the direction of neurotech. A pivotal moment would be the FDA approval of any implantable BCI for restoration of motor function in paralysis. The coming year is also likely to bring wider use of AI-driven neuro-assessment tools in telehealth as reimbursement frameworks tighten and real-world evidence accumulates.

The MedTech investment landscape for 2026

Two distinct MedTech tiers will continue to define the 2026 investment landscape:

Tier 1: Platform leaders

Companies with FDA clearances, established commercial operations, and recurring revenue are generally viewed as more mature and stable. This tier is attracting significant interest from later-stage investors and PE firms in particular, as illustrated by the $18.3 billion Hologic acquisition in October 2025. For R&D leaders, this points towards the growing importance of platform architectures that support multiple product lines and integrate data capabilities, rather than standalone devices.

Tier 2: Early-stage innovators

Companies with breakthrough technologies but limited clinical validation face a challenging fundraising environment. Seed and Series A start-ups collectively raised $720 million in Q1 2025, up from $605 million in Q1 2024. However, the overall number of deals fell, suggesting a more selective early-stage market. In this context, non-dilutive funding – such as grants, SBIR/STTR awards, EU Horizon opportunities – is important to sustain development and generate the evidence needed for future financing rounds.

Between these tiers lies a middle ground of start-ups with Series B funding and limited clinical validation. In addition, there are a large number of SMEs with limited product portfolios and moderate growth. Many of these companies face capital constraints: they may lack the resources for larger clinical trials or commercial scale-up, but securing further rounds of institutional investment can be difficult. These dynamics could drive consolidation or result in financing rounds that reset their valuations.

There is also evidence of growth in ‘build-to-buy-back’ ventures, in which MedTech companies co-found start-ups with investors to de-risk early innovation while retaining an exclusive option to acquire the technology later. A recent example is Olympus and Revival Healthcare Capital’s launch of Swan EndoSurgical in July 2025. The venture is backed by up to $458 million in milestone-linked funding to develop an endoluminal robotic system for gastrointestinal care.

Industry discussions at LSI USA 25 and Deloitte’s 2025 outlook suggest a strategic rationale for this approach: keep early-stage development off balance sheet, secure pipeline alignment, and accelerate speed-to-market. We expect this model to become a fixture of the MedTech R&D landscape in 2026, particularly for high-risk, high-reward technologies where traditional M&A feels too exposed.

Regulatory forces are shaping the investment environment too. The FDA’s update to the Quality Management System Regulation, aligning it with ISO 13485:2016, is the most significant change to US device quality standards in decades. While harmonization should reduce duplicative compliance across multiple markets, it increases near-term compliance costs and audit complexity.

Alongside this, greater focus on post-market surveillance heightens FDA expectations around evidence. Companies must now plan for ongoing real-world evidence collection and more robust post-market reporting, increasing operational spend and extending breakeven timelines.

These factors have clear implications for investors: companies without strong regulatory and quality infrastructures are at higher risk of approval delays, post-market compliance failures, and potential recalls. The uptick in FDA warning letters citing Quality System Regulation violations underlines this point. Assessment of regulatory readiness, quality system maturity, and post-market surveillance capabilities are becoming as important to due diligence as clinical data and market opportunity.

The road ahead for MedTech

In 2026, the MedTech investment landscape will favor companies that combine technical innovation, clinical evidence, and credible commercial pathways.

R&D leaders need to make evidence generation a core capability, with clinical studies designed to address payer questions as well as regulatory requirements. Quality and cybersecurity infrastructure should be established early, and clarity on reimbursement – not just technical performance – is key.

From an investor perspective, the focus is shifting. Chasing the newest AI algorithm or the most sophisticated neural interface is not as important as recognizing which technologies can genuinely change clinical practice. Surgical systems that improve outcomes while reducing costs, diagnostic platforms that redefine screening protocols, and neurotech that adapts to the patient in real-time are innovation areas with a clear path to clinical adoption.

How Sagentia Medical can help

MedTech innovation presents a high level of technical and strategic complexity. Sagentia Medical holds the deep scientific expertise and commercial understanding to help navigate product development challenges and support the journey from breakthrough technology to market-leading platform. Contact us to find out more.